Question · asked by 1 review
IVIg vs placebo: Change in mean disability score at 24 weeks or later
- Population
- people with CIDP
- Intervention
- IVIg
- Comparison
- placebo
- Outcome
- Change in mean disability score at 24 weeks or later
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Intravenous immunoglobulin vs placebo Change in mean disability score at 24 weeks or later · people with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 117 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- IVIg vs prednisolone · people with CIDP · 1 review
- IVIg vs intravenous methylprednisolone · people with CIDP · 1 review
- IVIg vs plasma exchange · people with CIDP · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.